Acurx Pharmaceuticals (ACXP) Projected to Release Earnings on Friday

Acurx Pharmaceuticals (NASDAQ:ACXP) is anticipated to announce its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect Acurx Pharmaceuticals to post earnings of ($0.42) per share for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 8:00 AM ET.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). On average, analysts expect Acurx Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acurx Pharmaceuticals Stock Up 4.8%

Shares of NASDAQ:ACXP opened at $1.54 on Thursday. The firm has a market capitalization of $6.62 million, a PE ratio of -0.38 and a beta of -2.03. Acurx Pharmaceuticals has a twelve month low of $1.33 and a twelve month high of $8.34. The company has a 50-day moving average price of $1.53 and a two-hundred day moving average price of $2.22.

Institutional Investors Weigh In On Acurx Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC purchased a new position in Acurx Pharmaceuticals during the fourth quarter worth about $27,000. Geode Capital Management LLC bought a new position in Acurx Pharmaceuticals in the 4th quarter worth about $31,000. Millennium Management LLC purchased a new stake in shares of Acurx Pharmaceuticals in the 4th quarter valued at about $103,000. Finally, Armistice Capital LLC purchased a new stake in shares of Acurx Pharmaceuticals in the 2nd quarter valued at about $551,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ACXP. Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen raised Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).